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Development of Oxetane Modified Building Blocks for Peptide 
Synthesis 
Stefan Roesner,a Jonathan D. Beadle,a Leo K. B. Tam,a Ina Wilkening,a Guy J. Clarkson,a Piotr 
Raubob and Michael Shipman*a
The synthesis and use of oxetane modified dipeptide building 
blocks in solution and solid-phase peptide synthesis (SPPS) is 
reported. The preparation of building blocks containing non-
glycine residues at the N-terminus in a stereochemically controlled 
manner is challenging. Here, a practical 4-step route to such 
building blocks is demonstrated, through the synthesis of 
dipeptides containing contiguous alanine residues. The 
incorporation of these new derivatives at specific sites along the 
backbone of an alanine-rich peptide sequence containing eighteen 
amino acids is demonstrated via solid-phase peptide synthesis. 
Additionally, new methods to enable the incorporation of all 20 of 
the proteinogenic amino acids into such dipeptide building blocks 
are reported through modifications of the synthetic route (for Cys 
and Met) and by changes to the protecting group strategy (for His, 
Ser and Thr).  
Introduction 
Peptides and peptidomimetics attract considerable attention as 
therapeutic agents due to their synthetic accessibility, high 
degree of specific binding, and their ability to target protein 
surfaces, one of the most challenging biological targets.1,2 Much 
of this work has focused on the development of 
peptidomimetics, to overcome issues with proteolytic stability 
and pharmacokinetic properties of conventional peptides.3 An 
increasing number of approved therapeutics and clinical 
candidates are based on peptidomimetics, and this area 
continues to offer enormous potential for drug development.4 
Recently, the four-membered oxetane ring has found 
application in peptide science,5,6,7 and more generally in 
medicinal chemistry,8 as a bioisosteric replacement for the 
carbonyl group. This work has led to the development of a new 
type of peptidomimetic, in which one or more of the backbone 
amide C=O bonds is substituted with an oxetane ring (Figure 
1a).6,7 As proteolysis revolves around peptide bond cleavage, 
replacing an amide bond with a non-cleavable oxetane residue 
should increase the metabolic stability of peptidomimetics, 
while minimally disturbing the overall structure. Indeed, the 
increased proteolytic stability of an oxetane modified dipeptide 
able to form hydrogels has recently been demonstrated.9 
Additionally, Carreira has shown that an oxetane modified Leu-
enkephalin analogue is less vulnerable towards proteolytic 
degradation increasing its serum half-life while retaining in vivo 
analgesic properties.10  
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(a) Generalised strategy for replacement of backbone C=O with oxetane ring:
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In order to study the impact of oxetane modification on the 
structure and properties of a range of biologically important 
peptides, we have previously developed a solid-phase peptide 
synthesis (SPPS) strategy to oxetane modified peptides (OMPs) 
using orthogonally protected dipeptide building blocks 3 
(Figure 1b).11 These compounds are readily accessible from C-
terminal protected amino acid and nitroalkenes via conjugate 
addition followed by reduction of the nitro group and in situ 
Fmoc protection. After hydrolysis of the C-terminus cumyl 
ester, the utility of these building blocks was demonstrated 
through the preparation of OMP analogues of several naturally 
occurring linear and cyclic peptides via SPPS (Figure 1c).11,12 
Clearly, there is considerable scope to use this chemistry to 
make much larger and more complex OMP libraries for 
medicinal chemistry.13 However, the feasibility of this is 
hampered by the rather incomplete coverage of R1 and R2 
within the dipeptide building blocks. Within 3, R1 has been 
essentially restricted to hydrogen,14 allowing access to oxetane 
modified glycine residues only (Figure 1b). Furthermore, with 
respect to R2, only nine of the twenty proteinogenic amino 
acids (A, D, F, G, K, P, R, S, and V) have been incorporated.11,12 
Of the remaining R2 side chains, incompatibility with one or 
more steps in the synthesis were foreseen (Figure 1b).11 Here, 
we report improved synthetic routes to the building blocks that 
allow all twenty proteinogenic amino acids to be installed at R2. 
Additionally, we extend the method such that it offers a 
strategy to building blocks where R1 ≠ H. This is illustrated by 
the synthesis of Fmoc-AOx-Ala-OCumyl15 and its use in the site-
specific replacement of various C=O bonds along an eighteen-
residue helical peptide by SPPS.  
Results and Discussion 
Preparation of alanine-derived oxetane modified building blocks 
We began by exploring the synthesis of protected building 
block 3 in which R1 ≠ H (Figure 1b). Specifically, we chose to 
focus on the synthesis of alanine based system, Fmoc-AOx-Ala-
OCumyl where R1, R2 = Me. Previous work suggested that 
conjugate addition of a chiral amine to nitroalkene 5 would 
proceed without stereocontrol leading to a mixture of 
diastereoisomers.6 Indeed, when H-Ala-OCumyl (6) was added 
to nitroalkene 5, a 50:50 mixture of diastereomers 7 was 
formed (Scheme 1a). Unfortunately, it was neither possible to 
separate these diastereomers after conjugate addition nor 
after reduction of the nitro group and Fmoc protection. As an 
alternative, we investigated the addition of α-
methylbenzylamine, (R)-8 to nitroalkene 5 to generate a 60:40 
mixture of diastereoisomers (Scheme 1b). In this case, the 
isolation of the major diastereomer could be readily achieved 
by column chromatography to provide (S,R)-9 with >95:5 dr in 
good yield. Reduction of the nitro group and cleavage of α-
methylbenzylamine using catalytic hydrogenation gave the 
corresponding 1,2-diamine. Finally, the sterically less hindered 
amine was selectively protected with FmocOSu to provide (S)-
10. Correspondingly (R)-10 was synthesised starting from 
nitroalkene 5 and (S)-8.16 The absolute configuration of 
compound (R)-10 was unambiguously confirmed by X-ray 
crystal structure analysis after acylation with 4-bromobenzoyl 
chloride (Scheme 1c).16 
 
Scheme 1. (a) Addition of H-Ala-OCumyl (6) to nitroalkene 5; (b) synthesis of 
enantiopure amino oxetane (S)-10 via conjugate addition of α-methylbenzamine, 
(R)-8 to 5; (c) proof of absolute stereoconfiguration via XRD. a Determined by 1H 
NMR analysis of the crude reaction mixture. b Major diastereoisomer isolated in 
>95:5 dr as determined by 1H NMR. 
Applying a strategy previously developed by Carreira,10 triflate 
13 was prepared in situ from hydroxyester (R)-12, derived from 
L-(+)-lactic acid after cumyl ester formation (2-phenyl-2-
methylethyl ester), Mitsunobu inversion and hydrolysis.16 The 
cumyl ester was chosen as C-terminal protecting group as it can 
be quantitatively hydrolysed under weakly acidic conditions 
with only 2% TFA leaving other acid sensitive amino acid side 
chain protecting groups untouched.17 Nucleophilic substitution 
of triflate 13 with (S)-10 provided the desired oxetane modified 
dipeptide building block Fmoc-AOx-Ala-OCumyl, (S,S)-14 
(Scheme 2). Correspondingly oxetane modified (R,S)-14 was 
prepared from triflate 13 and stereoisomer (R)-10. Chiral HPLC 
analysis confirmed that both building blocks were single 
diastereomers, indicating that the substitution proceeds 
exclusively in an SN2 fashion without epimerisation.18 Using the 
same reaction sequence outlined in Scheme 2 starting from (S)-
12, the cumyl ester of L-(+)-lactic acid, the preparation of 
stereoisomeric building blocks (S,R)-14 and (R,R)-14 would be 
possible in an analogous manner. 
Next, we sought to confirm that these new alanine based 
building blocks can be integrated into conventional SPPS. 
Alanine-rich peptide 18 forms a stable and well-characterised 
-helix that has previously been used to probe the impact of 
site-specific structural changes on helix stability and secondary 
structure.19 Hence, the synthesis of derivatives of 18 in which 
specific C=O amide bonds are replaced by oxetane rings would 
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helix stability.20 Using Fmoc-AOx-Ala-OCumyl, (S,S)-14, or 
previously reported Fmoc-GOx-Ala-OCumyl (15),12,15 we have 
successfully synthesised three such derivatives 19-21 using 
SPPS (Table 1). After initial acid catalysed deprotection of the 
C-terminal cumyl ester to give 16 and 17 (Scheme 3a),17 the 
building blocks were successfully incorporated into the growing 
peptide chain by double, manual couplings. The final peptides 
19-21 were isolated in good purity after preparative, reverse-
phase HPLC (Scheme 3b).16 
 
Scheme 2. Preparation of oxetane modified dipeptide building blocks (S,S)-14 and 
(R,S)-14 Fmoc-AOx-Ala-OCumyl. a Determined by chiral HPLC. 
  
Scheme 3. (a) C-terminal deprotection of dipeptide building blocks; (b) solid-
phase synthesis of OMPs with eighteen amino acid residues. Key: N-
methylmorpholine (NMM), triisopropylsilane (TIS). 
Table 1. Synthesis of alanine-rich OMPs by SPPS. 
Entry Peptide Sequence 
HRMS Purity 





























a Measured at 212 nm, lowest purity of two gradient runs. 
 
Preparation of glycine-derived oxetane modified building blocks 
We sought to expand the synthesis of oxetane modified 
dipeptide building blocks of the general type Fmoc-GOx-AA-
OCumyl to include all twenty of the proteinogenic amino acids. 
First, following our previously reported synthetic strategy, new 
cumyl esters 1a-g were prepared.11 After Fmoc deprotection, 
conjugate addition to 3-(nitromethylene)oxetane afforded 
nitroalkenes 2a-g in moderate to good yield (Table 2, step 1). 
Then, reduction of the nitro group using hydrogen and Raney 
nickel in the presence of FmocOSu gave the required oxetane 
modified dipeptide building blocks Fmoc-GOx-AA-OCumyl 3a-g 
for a range of amino acids (Table 2, step 2). While some of the 
transformations proceeded in modest yields, the strength of 
this methodology lies in the structural variety and scalability of 
the procedure providing enatiomerically pure and bench-stable 
derivatives 3a-g. 
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Unfortunately, for amino acids containing sulfur, Cys and Met, 
Raney nickel reduction of nitro alkenes 2h and 2i led to partial 
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reduction of the nitro group was required. This problem was 
solved by using Zn dust and acetic acid for the reduction step 
providing access to Cys- and Met-containing dipeptide building 
blocks 3h and 3i (Scheme 4).21 Notably, the cumyl ester was not 
hydrolysed under the acidic reductive conditions. We note 
however that these conditions are generally less efficient than 
the Raney Ni reduction, and so are recommended only for the 
synthesis of sulfur containing building blocks.  
 
Scheme 4. Synthesis of Cys- and Met-containing dipeptide building blocks 3h and 3i. 
Unfortunately, the C-terminal cumyl ester protecting group 
proved unsuitable for three amino acids. When oxetane 
modified dipeptide building block Fmoc-GOx-His(Trt)-OCumyl 
(3j) was treated with 2% TFA in dichloromethane, concomitant 
deprotection of the acid labile trityl group was observed giving 
a mixture of dipeptide building block 4j and Trt-deprotected 22 
(Scheme 5a). An additional problem arose during the 
deprotection of tert-butyl protected aliphatic alcohols after 
incorporation into peptide sequences. Removal of the tert-
butyl groups of either Ser(tBu) or Thr(tBu) required high 
concentrations of TFA leading partially to diol 23 caused by 
hydrolysis of the four-membered oxetane ring upon extended 
acid treatment (Scheme 5b). Alternatively, replacing the tert-
butyl group on Ser and Thr with a more labile trityl group led to 
partial deprotection during hydrolysis of the cumyl ester as 
previously observed for 3j.  
 
Scheme 5. (a) Hydrolysis of Fmoc-GOx-His(Trt)-OCumyl (3j); (b) ring-opening of 
the oxetane ring with 70% TFA. 
On investigation, replacing the C-terminal cumyl group with a 
simple benzyl ester was the best approach for building blocks 
containing His, Ser or Thr. Following the same strategy starting 
from the Fmoc-protected amino acids, C-terminal benzyl 
protection, Fmoc-deprotection followed by conjugate addition 
to 3-(nitromethylene)oxetane, and Raney nickel-mediated 
reduction in the presence of FmocOSu gave oxetane modified 
dipeptide building blocks 3k-m (Scheme 6).  
 
Scheme 6. Synthesis of oxetane containing benzyl ester dipeptide building blocks 
3k-m. 
These orthogonally protected building blocks enabled peptide 
coupling after cleavage of the C-terminal benzyl group via Pd-
catalysed hydrogenolysis. Previously we reported undesired 
deprotection of the N-terminal Fmoc group during reduction of 
C-terminal benzyl esters.11 This side reaction can be largely 
suppressed by carefully monitoring the reaction progress.16 The 
reductions were best carried out in DMF in order to avoid 
solubility problems of the carboxylic acids, which were used 
after filtration without further purification. The application of 
3k-m in peptide couplings was demonstrated in solution-phase 
(Scheme 7a) and in SPPS (Scheme 7b). Importantly, peptides 
24-26 fully retain their labile trityl protecting groups during 
these sequences (cf. Scheme 5a). Moreover, analysis by 1H 
NMR confirmed that no detectable epimerisation arose during 
these couplings. These experiments demonstrate that benzyl 
protected dipeptide building blocks provide a solution for 
amino acids that are not compatible with C-terminal cumyl 
ester protection. Taken together with previous studies,11,12 the 
synthesis of glycine-derived oxetane modified building blocks 
Fmoc-GOx-AA-OR, 3 has now been extended to all twenty 
proteinogenic amino acids. 
 
Scheme 7. Use of benzyl ester deprotection strategy in preparation of oxetane 
modified peptides in (a) solution and (b) on solid phase. 
Conclusions 
We have generalised our strategy for the preparation and use 
of oxetane containing dipeptide building blocks in solution and 
solid-phase peptide synthesis. The methodology has been 
expanded to residues beyond glycine at the N-terminus as 
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oxetane modified alanine 14. Either enantiomer of Fmoc-
protected diamine 10 can be made in three simple steps and 
22% overall yield. This chemistry reported is much more 
amenable than earlier work that required twelve steps to 
provide the corresponding Boc or Cbz-protected variant of this 
diamine.10 The approach has potential to be expanded to 
residues bearing other side chains. Reaction of enantiopure 10 
with trifluorosulfonates of hydroxy esters provides oxetane 
modified dipeptide building block 14. The strategy allows 
access to all four stereoisomers of 14 using one unified 
procedure. The incorporation of these new derivatives at 
specific sites along the backbone of an alanine-rich peptide 
sequence containing eighteen amino acids is demonstrated via 
SPPS. At the C-terminus, we have improved the chemistry such 
that all twenty of the proteinogenic amino acids can be 
introduced in three simple synthetic steps. Specifically, for 
sulfur-containing amino acids, the procedure for the nitro 
reduction had to be adjusted to avoid partial desulfurisation of 
the side chain. For amino acids containing acid-sensitive trityl-
protected side chains, His, Ser and Thr, the C-terminal cumyl 
ester was replaced by a simple benzyl group without detriment. 
With this expanded set of building blocks at our disposal, we 
are now well placed to explore their application in the synthesis 
of structurally interesting and biologically active 
peptidomimetics. 
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